Clinical Trial Update: Savolitinib vs. Sunitinib in MET-driven PRCC. [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing savolitinib to sunitinib in MET-driven papillary renal cell carcinoma has posted results and is not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Papillary Renal Cell Carcinoma

Drugs mentioned

• Savolitinib (savolitinib)
• Sunitinib (sunitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Carcinoma, Carcinoma, Renal Cell | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2020-07-10